Yasmeen Rahimi
Stock Analyst at Piper Sandler
(3.37)
# 1,078
Out of 4,412 analysts
58
Total ratings
29.51%
Success rate
9.38%
Average return
Main Sectors:
Top Industries:
37 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Maintains: Overweight | $31 → $36 | $15.47 | +132.71% | 2 | Apr 16, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Overweight | $9 | $1.03 | +773.79% | 1 | Apr 4, 2024 | |
| KRRO Korro Bio | Maintains: Overweight | $180 | $62.93 | +186.03% | 2 | Mar 27, 2024 | |
| GOSS Gossamer Bio | Maintains: Overweight | $15 | $0.67 | +2,145.51% | 1 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Overweight | $336 | $193.33 | +73.80% | 3 | Mar 14, 2024 | |
| EWTX Edgewise Therapeutics | Initiates: Overweight | $48 | $16.17 | +196.85% | 1 | Mar 7, 2024 | |
| SVRA Savara | Maintains: Overweight | $7 → $16 | $4.41 | +262.81% | 2 | Mar 4, 2024 | |
| ANAB AnaptysBio | Initiates: Overweight | $80 | $21.00 | +280.95% | 1 | Feb 16, 2024 | |
| SLNO Soleno Therapeutics | Initiates: Overweight | $93 | $37.89 | +145.45% | 1 | Feb 5, 2024 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $37 | $21.99 | +68.26% | 1 | Jan 16, 2024 | |
| GPCR Structure Therapeutics | Maintains: Overweight | $58 → $93 | $38.94 | +138.83% | 3 | Oct 27, 2023 | |
| TRML Tourmaline Bio | Initiates: Overweight | $65 | $15.68 | +314.54% | 1 | Oct 25, 2023 | |
| IMVT Immunovant | Maintains: Overweight | $28 → $57 | $27.17 | +109.79% | 2 | Oct 24, 2023 | |
| SGMT Sagimet Biosciences | Initiates: Overweight | $67 | $4.06 | +1,550.25% | 1 | Aug 8, 2023 | |
| PTGX Protagonist Therapeutics | Reiterates: Overweight | $35 | $25.15 | +39.17% | 3 | Jul 3, 2023 | |
| SLRN Acelyrin | Initiates: Overweight | $68 | $4.24 | +1,503.77% | 1 | May 30, 2023 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Overweight | $56 | $42.12 | +32.95% | 2 | Apr 24, 2023 | |
| ALLK Allakos | Initiates: Overweight | $22 | $1.02 | +2,056.86% | 1 | Mar 7, 2023 | |
| ENTA Enanta Pharmaceuticals | Maintains: Overweight | $87 | $12.37 | +603.31% | 3 | Feb 8, 2023 | |
| PRTA Prothena Corporation | Initiates: Overweight | $94 | $20.87 | +350.41% | 1 | Jan 27, 2023 | |
| ALGS Aligos Therapeutics | Maintains: Overweight | $3 → $7 | $0.78 | +795.14% | 4 | Jan 17, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Overweight | $10 | $1.58 | +532.91% | 1 | Aug 12, 2022 | |
| CYTK Cytokinetics | Maintains: Overweight | $50 → $72 | $65.34 | +10.19% | 1 | Jun 10, 2022 | |
| PRAX Praxis Precision Medicines | Maintains: Overweight | $975 → $270 | $54.80 | +392.70% | 2 | Jun 8, 2022 | |
| RPHM Reneo Pharmaceuticals | Maintains: Overweight | $45 → $18 | $1.67 | +977.84% | 2 | May 18, 2022 | |
| PLRX Pliant Therapeutics | Maintains: Overweight | $63 → $27 | $11.81 | +128.62% | 1 | May 18, 2022 | |
| IMUX Immunic | Maintains: Overweight | $71 → $39 | $1.22 | +3,096.72% | 2 | May 18, 2022 | |
| ETNB 89bio | Maintains: Overweight | $54 → $19 | $8.26 | +130.02% | 2 | May 18, 2022 | |
| ALT Altimmune | Maintains: Overweight | $34 → $25 | $7.26 | +244.35% | 2 | May 18, 2022 | |
| VTYX Ventyx Biosciences | Initiates: Overweight | n/a | $3.93 | - | 1 | Nov 15, 2021 | |
| TNYA Tenaya Therapeutics | Initiates: Overweight | n/a | $4.31 | - | 1 | Aug 24, 2021 | |
| VXRT Vaxart | Initiates: Overweight | n/a | $0.71 | - | 1 | Jun 11, 2021 | |
| DSGN Design Therapeutics | Initiates: Overweight | n/a | $3.78 | - | 1 | Apr 20, 2021 | |
| AMRN Amarin Corporation | Initiates: Overweight | n/a | $0.87 | - | 1 | Aug 26, 2020 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Overweight | n/a | $26.55 | - | 1 | Aug 26, 2020 | |
| LUMO Lumos Pharma | Initiates: Overweight | n/a | $2.77 | - | 1 | Aug 26, 2020 | |
| MIRM Mirum Pharmaceuticals | Initiates: Overweight | n/a | $24.46 | - | 1 | Jul 31, 2020 |
Verona Pharma
Apr 16, 2024
Maintains: Overweight
Price Target: $31 → $36
Current: $15.47
Upside: +132.71%
Unicycive Therapeutics
Apr 4, 2024
Initiates: Overweight
Price Target: $9
Current: $1.03
Upside: +773.79%
Korro Bio
Mar 27, 2024
Maintains: Overweight
Price Target: $180
Current: $62.93
Upside: +186.03%
Gossamer Bio
Mar 27, 2024
Maintains: Overweight
Price Target: $15
Current: $0.67
Upside: +2,145.51%
Madrigal Pharmaceuticals
Mar 14, 2024
Reiterates: Overweight
Price Target: $336
Current: $193.33
Upside: +73.80%
Edgewise Therapeutics
Mar 7, 2024
Initiates: Overweight
Price Target: $48
Current: $16.17
Upside: +196.85%
Savara
Mar 4, 2024
Maintains: Overweight
Price Target: $7 → $16
Current: $4.41
Upside: +262.81%
AnaptysBio
Feb 16, 2024
Initiates: Overweight
Price Target: $80
Current: $21.00
Upside: +280.95%
Soleno Therapeutics
Feb 5, 2024
Initiates: Overweight
Price Target: $93
Current: $37.89
Upside: +145.45%
NewAmsterdam Pharma Company
Jan 16, 2024
Initiates: Overweight
Price Target: $37
Current: $21.99
Upside: +68.26%
Structure Therapeutics
Oct 27, 2023
Maintains: Overweight
Price Target: $58 → $93
Current: $38.94
Upside: +138.83%
Tourmaline Bio
Oct 25, 2023
Initiates: Overweight
Price Target: $65
Current: $15.68
Upside: +314.54%
Immunovant
Oct 24, 2023
Maintains: Overweight
Price Target: $28 → $57
Current: $27.17
Upside: +109.79%
Sagimet Biosciences
Aug 8, 2023
Initiates: Overweight
Price Target: $67
Current: $4.06
Upside: +1,550.25%
Protagonist Therapeutics
Jul 3, 2023
Reiterates: Overweight
Price Target: $35
Current: $25.15
Upside: +39.17%
Acelyrin
May 30, 2023
Initiates: Overweight
Price Target: $68
Current: $4.24
Upside: +1,503.77%
Crinetics Pharmaceuticals
Apr 24, 2023
Initiates: Overweight
Price Target: $56
Current: $42.12
Upside: +32.95%
Allakos
Mar 7, 2023
Initiates: Overweight
Price Target: $22
Current: $1.02
Upside: +2,056.86%
Enanta Pharmaceuticals
Feb 8, 2023
Maintains: Overweight
Price Target: $87
Current: $12.37
Upside: +603.31%
Prothena Corporation
Jan 27, 2023
Initiates: Overweight
Price Target: $94
Current: $20.87
Upside: +350.41%
Aligos Therapeutics
Jan 17, 2023
Maintains: Overweight
Price Target: $3 → $7
Current: $0.78
Upside: +795.14%
Lexicon Pharmaceuticals
Aug 12, 2022
Initiates: Overweight
Price Target: $10
Current: $1.58
Upside: +532.91%
Cytokinetics
Jun 10, 2022
Maintains: Overweight
Price Target: $50 → $72
Current: $65.34
Upside: +10.19%
Praxis Precision Medicines
Jun 8, 2022
Maintains: Overweight
Price Target: $975 → $270
Current: $54.80
Upside: +392.70%
Reneo Pharmaceuticals
May 18, 2022
Maintains: Overweight
Price Target: $45 → $18
Current: $1.67
Upside: +977.84%
Pliant Therapeutics
May 18, 2022
Maintains: Overweight
Price Target: $63 → $27
Current: $11.81
Upside: +128.62%
Immunic
May 18, 2022
Maintains: Overweight
Price Target: $71 → $39
Current: $1.22
Upside: +3,096.72%
89bio
May 18, 2022
Maintains: Overweight
Price Target: $54 → $19
Current: $8.26
Upside: +130.02%
Altimmune
May 18, 2022
Maintains: Overweight
Price Target: $34 → $25
Current: $7.26
Upside: +244.35%
Ventyx Biosciences
Nov 15, 2021
Initiates: Overweight
Price Target: n/a
Current: $3.93
Upside: -
Tenaya Therapeutics
Aug 24, 2021
Initiates: Overweight
Price Target: n/a
Current: $4.31
Upside: -
Vaxart
Jun 11, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.71
Upside: -
Design Therapeutics
Apr 20, 2021
Initiates: Overweight
Price Target: n/a
Current: $3.78
Upside: -
Amarin Corporation
Aug 26, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.87
Upside: -
Arcturus Therapeutics Holdings
Aug 26, 2020
Initiates: Overweight
Price Target: n/a
Current: $26.55
Upside: -
Lumos Pharma
Aug 26, 2020
Initiates: Overweight
Price Target: n/a
Current: $2.77
Upside: -
Mirum Pharmaceuticals
Jul 31, 2020
Initiates: Overweight
Price Target: n/a
Current: $24.46
Upside: -